131 related articles for article (PubMed ID: 31706195)
1. Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.
Tischer A; Antelo G; Coltro G; Finke CM; Gonsalves W; Pardanani A; Ketterling R; Mangaonkar A; Gangat N; Tefferi A; Patnaik MM; Lasho TL
Leuk Res; 2019 Dec; 87():106264. PubMed ID: 31706195
[No Abstract] [Full Text] [Related]
2. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
[No Abstract] [Full Text] [Related]
3. A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms.
Sakata-Yanagimoto M; Yokoyama Y; Muto H; Obara N; Kurita N; Kato T; Hasegawa Y; Miyazaki Y; Kurokawa M; Chiba S
Ann Hematol; 2016 Apr; 95(5):829-30. PubMed ID: 26891876
[No Abstract] [Full Text] [Related]
4. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
[TBL] [Abstract][Full Text] [Related]
5. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
[TBL] [Abstract][Full Text] [Related]
6. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
[No Abstract] [Full Text] [Related]
7. Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Snyder R; Libby T; Raciti P; Amin B; Jacobson M; Rakheja D; Fleming K; Bartenstein M; Zhu C; Goel S; Verma AK; Shastri A
Anticancer Res; 2018 Apr; 38(4):2201-2205. PubMed ID: 29599340
[TBL] [Abstract][Full Text] [Related]
8. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Andrulis M; Capper D; Luft T; Hartmann C; Zentgraf H; von Deimling A
Leuk Res; 2010 Aug; 34(8):1091-3. PubMed ID: 20227112
[TBL] [Abstract][Full Text] [Related]
9. The molecular landscape of childhood myeloproliferative neoplasms.
Langabeer SE; Haslam K; McMahon C
Leuk Res; 2014 Aug; 38(8):997-8. PubMed ID: 24986380
[TBL] [Abstract][Full Text] [Related]
10. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A
Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661
[TBL] [Abstract][Full Text] [Related]
11. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.
Wang X; Muramatsu H; Okuno Y; Sakaguchi H; Yoshida K; Kawashima N; Xu Y; Shiraishi Y; Chiba K; Tanaka H; Saito S; Nakazawa Y; Masunari T; Hirose T; Elmahdi S; Narita A; Doisaki S; Ismael O; Makishima H; Hama A; Miyano S; Takahashi Y; Ogawa S; Kojima S
Haematologica; 2015 Oct; 100(10):e398-401. PubMed ID: 26022708
[No Abstract] [Full Text] [Related]
12. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
[No Abstract] [Full Text] [Related]
13. Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms.
Guglielmelli P; Pacilli A; Coltro G; Mannelli F; Mannelli L; Contini E; Rotunno G; Bartalucci N; Fiaccabrino S; Sordi B; Loscocco GG; Paoli C; Vannucchi AM
Am J Hematol; 2020 Jan; 95(1):E23-E26. PubMed ID: 31659782
[No Abstract] [Full Text] [Related]
14. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
15. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.
Caramazza D; Lasho TL; Finke CM; Gangat N; Dingli D; Knudson RA; Siragusa S; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
Leukemia; 2010 Dec; 24(12):2120-2. PubMed ID: 20861910
[No Abstract] [Full Text] [Related]
16. A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.
Chou WC; Huang YN; Huang CF; Tseng MH; Tien HF
Blood; 2010 Jul; 116(3):495-6. PubMed ID: 20651083
[No Abstract] [Full Text] [Related]
17. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Score J; Hidalgo-Curtis C; Jones AV; Winkelmann N; Skinner A; Ward D; Zoi K; Ernst T; Stegelmann F; Döhner K; Chase A; Cross NC
Blood; 2012 Feb; 119(5):1208-13. PubMed ID: 22053108
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
Saint-Martin C; Leroy G; Delhommeau F; Panelatti G; Dupont S; James C; Plo I; Bordessoule D; Chomienne C; Delannoy A; Devidas A; Gardembas-Pain M; Isnard F; Plumelle Y; Bernard O; Vainchenker W; Najman A; Bellanné-Chantelot C;
Blood; 2009 Aug; 114(8):1628-32. PubMed ID: 19564637
[TBL] [Abstract][Full Text] [Related]
19. The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.
Meggendorfer M; Haferlach C; Zenger M; Macijewski K; Kern W; Haferlach T
Leukemia; 2016 Jul; 30(7):1624-7. PubMed ID: 26859077
[No Abstract] [Full Text] [Related]
20. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
[No Abstract] [Full Text] [Related]
[Next] [New Search]
